5月22日,歌礼制药-B(01672)发布公告,宣布其自主研发的口服小分子IL-17抑制剂ASC50治疗银屑病的新药临床试验申请已获得美国FDA批准。ASC50在临床前研究中显示出比当前临床开发阶段的其他口服小分子IL-17抑制剂更高的药物暴露量、更长的半衰期以及更低的清除率,表明其有望成为同类最佳的口服药物。
(文章来源:财中社)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.